data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Lexaria Bioscience

(NASDAQ:LEXX)

Intraday

$2.18

-0.085[-3.75%]

After-Hours

$2.18

0[0.00%]

Perks Buy Compare Brokers

$2.18

-0.085[-3.75%]

At close: Apr 22

$2.18

0[0.00%]

After Hours: 4:33PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Lexaria Bioscience Stock (NASDAQ:LEXX)

Lexaria Bioscience Stock (NASDAQ: LEXX)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, April 16, 2024

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights - 6 days ago
Lexaria Receives Ethics Review Board Approval To Begin New GLP-1 Study, Investigating GLP-1 Drugs And DehydraTECH
Benzinga Newsdesk - 6 days ago

Thursday, March 14, 2024

Lexaria Appoints Nelson Cabatuan As Chief Financial Officer, Effective Immediately
Benzinga Newsdesk - Mar 14, 2024, 9:22AM

Tuesday, March 12, 2024

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor - Mar 12, 2024, 2:07PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Mar 12, 2024, 1:31PM

Thursday, March 07, 2024

Lexaria Bioscience Hires Contract Research Organization To Perform Co.'s Next GLP-1 Human Pilot Study
Benzinga Newsdesk - Mar 7, 2024, 9:08AM

Tuesday, March 05, 2024

Maxim Group Maintains Buy on Lexaria Bioscience, Raises Price Target to $12
Benzinga Newsdesk - Mar 5, 2024, 11:41AM
Watching Lexaria Bioscience; Traders Circulate Analyst Comments Suggesting "DehydraTECH Platform For The Delivery Of GLP-1 Drugs With A Comprehensive Development Program Could Produce A Compelling Data Package To Partner The Technology"
Benzinga Newsdesk - Mar 5, 2024, 11:27AM
Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Benzinga Newsdesk - Mar 5, 2024, 9:10AM

Friday, March 01, 2024

Lexaria Announces FDA Clearance For Its Planned U.S. Phase 1b Hypertension Clinical Trial
Benzinga Newsdesk - Mar 1, 2024, 8:22AM

Wednesday, February 28, 2024

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Feb 28, 2024, 4:31PM

Tuesday, February 27, 2024

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights - Feb 27, 2024, 4:31PM

Thursday, February 15, 2024

Why Lexaria Bioscience (LEXX) Shares Are Moving
Henry Khederian - Feb 15, 2024, 9:27AM
Lexaria Bioscience Announces $3.6M Registered Direct Offering Of 1,558,443 Shares At $2.31/Share
Benzinga Newsdesk - Feb 15, 2024, 8:21AM

Friday, February 09, 2024

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights - Feb 9, 2024, 12:31PM

Tuesday, January 30, 2024

Lexaria's Submits Investigational New Drug Application For Planned Phase 1B Trial Of DehydraTECH-CBD
Benzinga Newsdesk - Jan 30, 2024, 8:55AM

Tuesday, January 16, 2024

Lexaria Bioscience Unveils Planned 2024 GLP-1 Study Program
Benzinga Newsdesk - Jan 16, 2024, 9:14AM

Thursday, January 11, 2024

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
Benzinga Newsdesk - Jan 11, 2024, 8:43AM

Tuesday, January 09, 2024

Lexaria Bioscience Corp. Improves Delivery, Efficacy Of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
Benzinga Newsdesk - Jan 9, 2024, 8:47AM

Thursday, January 04, 2024

Lexaria's Patented Technology Improved The Oral Performance Of The Rybelsus-Branded GLP-1 Drug Semaglutide
Benzinga Newsdesk - Jan 4, 2024, 9:12AM

Thursday, December 07, 2023

Lexaria Bioscience Corp. Announces That The Co's Anticipated Submission Of An Investigational New Drug Application With The U.S. FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Is Expected To Be Filed Within ~45 Days
Benzinga Newsdesk - Dec 7, 2023, 9:22AM

Thursday, November 30, 2023

Lexaria Bioscience Corp Files For Resale Of Up To 1.6M Shares Of Common Stock By The Selling Stockholde
Benzinga Newsdesk - Nov 30, 2023, 4:18PM

Tuesday, November 28, 2023

Lexaria Bioscience Announces Additional Interim Results From Human Pilot Study Evaluating Dehydratechtm Technology For The Oral Delivery Of The Glucagon-Like Peptide-1 Drug Semaglutide Available In The Branded Product Rybelsus
Benzinga Newsdesk - Nov 28, 2023, 9:36AM

Monday, November 27, 2023

Lexaria Bioscience shares are trading higher after the company announced results from a human pilot study evaluating DehydraTECH technology for the oral delivery of semaglutide.
Benzinga Newsdesk - Nov 27, 2023, 3:23PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Nov 27, 2023, 12:30PM

Tuesday, November 21, 2023

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights - Nov 21, 2023, 4:31PM

Thursday, November 02, 2023

Lexaria Bioscience Secretary Awarded $18K Worth of Stock Options
Benzinga Insights - Nov 2, 2023, 11:01AM

Wednesday, November 01, 2023

Lexaria Bioscience Corp. Expands Studies Of Proprietary Platform In Multibillion-Dollar GLP-1 Drug Space
Benzinga Newsdesk - Nov 1, 2023, 8:31AM

Tuesday, October 31, 2023

Chief Executive Officer at Lexaria Bioscience Acquires Company Stock Options Worth 30,000 Shares
Benzinga Insights - Oct 31, 2023, 11:01AM
President at Lexaria Bioscience Acquires Company Stock Options Worth 30,000 Shares
Benzinga Insights - Oct 31, 2023, 11:00AM
Lexaria Bioscience Corp. Evaluating Proprietary Drug-Delivery Platform For Improved Efficacy Of GLP-1 Drugs
Benzinga Newsdesk - Oct 31, 2023, 8:43AM

Wednesday, October 18, 2023

On October 17, Lexaria Bioscience Corp Got Nasdaq Bid Price Deficiency Notice
Benzinga Newsdesk - Oct 18, 2023, 12:28PM

Friday, October 13, 2023

Lexaria Enters New Global Exclusive Collaboration And License Agreement With SulfoSyn; Global Exclusivity For All Non-Pharmaceutical Applications Of DehydraTECH-Sulforaphane Has Been Awarded
Happy Mohamed - Oct 13, 2023, 9:07AM

Thursday, October 12, 2023

Lexaria Granted Two New Patents In Canada; Canadian Patent #2,984,917 And Canadian Patent #3,111,082
Benzinga Newsdesk - Oct 12, 2023, 9:15AM

Friday, September 29, 2023

Lexaria Bioscience Announced A Registered Direct Offering Of 1.6M And Warrants To Purchase Up To 1.6M Shares At A Combined Price Of $0.97 With Gross Proceeds Of $1.6M
Benzinga Newsdesk - Sep 29, 2023, 8:07AM

Thursday, September 21, 2023

Lexaria To Evaluate Impact Of DehydraTECH On Oral Performance Of GLP-1 Drugs Used In Products Such As Ozempic, Wegovy And Rybelsus, Alone Or Together With DehydraTECH-CBD
Benzinga Newsdesk - Sep 21, 2023, 9:16AM

Wednesday, August 30, 2023

Lexaria Provides Update On Investigational New Drug Application Progress With The FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Designated As HYPER-H23-1
Happy Mohamed - Aug 30, 2023, 9:24AM

Monday, August 28, 2023

Lexaria Biosciences Says On Aug. 24 Co Received A Letter From NASDAQ Confirming The Cure Of NASDAQ Bid Price Deficiency
Benzinga Newsdesk - Aug 28, 2023, 2:54PM

Wednesday, August 09, 2023

Lexaria Bioscience Corp Report Results From Its 2023 Human Oral Nicotine Study NIC-H22-1 Comparing Lexaria's DehydraTECH-Nicotine Tobacco-Free Pouch To ZYN
Benzinga Newsdesk - Aug 9, 2023, 9:19AM

Wednesday, August 02, 2023

Lexaria's Plans To Study Weight Loss And Diabetes Control In A Human Clinical Study With DehydraTECH-CBD
Happy Mohamed - Aug 2, 2023, 9:14AM

Friday, July 28, 2023

Lexaria Incorporates New Subsidiary For CPG Products And Updates Human Nicotine Study
Happy Mohamed - Jul 28, 2023, 9:11AM

Wednesday, July 26, 2023

Director at Lexaria Bioscience Acquires Company Stock Options Worth 5,000 Shares
Benzinga Insights - Jul 26, 2023, 11:00AM
Lexaria Bioscience Board Member Awarded $3K Worth of Stock Options
Benzinga Insights - Jul 26, 2023, 11:00AM
Board Member at Lexaria Bioscience Acquires Company Stock Options Worth 5,000 Shares
Benzinga Insights - Jul 26, 2023, 11:00AM

Friday, July 21, 2023

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Benzinga Insights - Jul 21, 2023, 11:00AM
Maxim Group Initiates Coverage On Lexaria Bioscience with Buy Rating, Announces Price Target of $2
Benzinga Newsdesk - Jul 21, 2023, 10:00AM

Wednesday, July 19, 2023

Lexaria Granted Strategically Important New U.S. Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Happy Mohamed - Jul 19, 2023, 9:06AM

Tuesday, June 20, 2023

Lexaria Receives Four New Granted Patents
Benzinga Newsdesk - Jun 20, 2023, 9:07AM

Friday, June 16, 2023

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels In Diabetes Animal Study
Benzinga Newsdesk - Jun 16, 2023, 9:11AM

Monday, June 12, 2023

Lexaria Bioscience Appoints Mike Shankman As New CFO; Succeeds Greg Downey Effective Immediately
Benzinga Newsdesk - Jun 12, 2023, 9:24AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved